{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:37:13Z","timestamp":1792521433110,"version":"4.5.0"},"reference-count":26,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,6,1]]},"abstract":"<jats:p>OBJECTIVE. A refrigerator-stable formulation of ProQuad has been developed to expand the utility of ProQuad to areas in which maintenance of a frozen cold chain (\u221215\u00b0C or colder) during storage and transport may not be feasible. The objective of this study was to demonstrate that the immunogenicity and safety profiles of a refrigerator-stable formulation of ProQuad are similar to the recently licensed frozen formulation.<\/jats:p>\n               <jats:p>METHODS. In this double-blind, randomized, multicenter study, healthy 12- to 23-month-old children with negative vaccination and clinical histories for measles, mumps, rubella, varicella, and zoster were vaccinated with either the refrigerator-stable formulation of ProQuad (N = 1006) or the frozen formulation of ProQuad (N = 513). Patients were followed for 42 days after vaccination for adverse experiences. Immunogenicity was evaluated 6 weeks after vaccination.<\/jats:p>\n               <jats:p>RESULTS. The refrigerator-stable formulation of ProQuad was generally well tolerated. The incidence of adverse experiences was similar between groups. No vaccine-related serious adverse experiences were reported. For both groups, the response rate was \u226597.7% for measles, mumps, and rubella, and the percentage of patients with a varicella zoster virus antibody titer of \u22655 U\/mL glycoprotein antigen-based enzyme-linked immunosorbent assay after vaccination was \u226588.8%. The geometric mean titers for all antigens were numerically slightly higher in patients who received the refrigerator-stable formulation.<\/jats:p>\n               <jats:p>CONCLUSIONS. The refrigerator-stable formulation of ProQuad is generally well tolerated, highly immunogenic, and noninferior in terms of postvaccination antibody responses. This refrigerator-stable formulation may improve ease of vaccine administration, increase use of the vaccine throughout the world because of its improved storage conditions, and replace the frozen formulation of ProQuad or any dose of M-M-RII and Varivax in routine practice.<\/jats:p>","DOI":"10.1542\/peds.2006-2283","type":"journal-article","created":{"date-parts":[[2007,5,15]],"date-time":"2007-05-15T00:44:10Z","timestamp":1179189850000},"page":"e1299-e1305","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of the Safety and Immunogenicity of a Refrigerator-Stable Versus a Frozen Formulation of ProQuad (Measles, Mumps, Rubella, and Varicella Virus Vaccine Live)"],"prefix":"10.1542","volume":"119","author":[{"given":"Henry H.","family":"Bernstein","sequence":"first","affiliation":[{"name":"Dartmouth Medical School, Children's Hospital at Dartmouth, Lebanon, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Eves","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Campbell","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven B.","family":"Black","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry D.","family":"Twiggs","sequence":"additional","affiliation":[{"name":"Dixie Pediatrics, St George, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Reisinger","sequence":"additional","affiliation":[{"name":"Primary Physicians Research, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph M.","family":"Conti","sequence":"additional","affiliation":[{"name":"Foothills Pediatrics, Henderson, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl-Erik","family":"Flodmark","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Hospital, Universitetssjukhuset MAS, Malmo\u0308, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Rombo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Malarsjukhuset, Eskiltuna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Klopfer","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scho\u0308del","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hartzel","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Kuter","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and the Refrigerator-Stable Formulation Study Group for ProQuad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2007,6,1]]},"reference":[{"key":"2021120902024342300_R1","doi-asserted-by":"crossref","unstructured":"Bo\u0308ttiger M, Christenson B, Romanus V, Taranger J, Strandell A. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed).\u20081987;295:1264\u20131267","DOI":"10.1136\/bmj.295.6608.1264"},{"key":"2021120902024342300_R2","unstructured":"Centers for Disease Control and Prevention. Summary of notifiable diseases: United States, 1998. MMWR Morb Mortal Wkly Rep.\u20081999;47:ii\u201392"},{"key":"2021120902024342300_R3","unstructured":"Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 9th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2006:125\u2013170"},{"key":"2021120902024342300_R4","doi-asserted-by":"crossref","unstructured":"Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA.\u20082000;284:2643\u20132647","DOI":"10.1001\/jama.284.20.2643"},{"key":"2021120902024342300_R5","unstructured":"World Health Organization Vaccines and Biologicals. WHO Vaccine-Preventable Diseases: Monitoring System\u20142003 Global Summary. Geneva, Switzerland: World Health Organization; 2003"},{"key":"2021120902024342300_R6","unstructured":"Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage among children aged 19\u201335 months: United States, 2004. MMWR Morb Mortal Wkly Rep.\u20082005;54:717\u2013721"},{"key":"2021120902024342300_R7","doi-asserted-by":"crossref","unstructured":"Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995\u20132000. JAMA.\u20082002;287:606\u2013611","DOI":"10.1001\/jama.287.5.606"},{"key":"2021120902024342300_R8","unstructured":"Centers for Disease Control and Prevention. Decline in annual incidence of varicella: selected states, 1990\u20132001. MMWR Morb Mortal Wkly Rep.\u20082003;52:884\u2013885"},{"key":"2021120902024342300_R9","unstructured":"Centers for Disease Control and Prevention. Combination vaccines for childhood immunization. MMWR Recomm Rep.\u20081999;48(RR-5):1\u201314"},{"key":"2021120902024342300_R10","doi-asserted-by":"crossref","unstructured":"Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J.\u20082005;24:665\u2013669","DOI":"10.1097\/01.inf.0000172902.25009.a1"},{"key":"2021120902024342300_R11","doi-asserted-by":"crossref","unstructured":"Shinefield H, Williams W, Marchant C, et al. Dose-response of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J.\u20082005;24:670\u2013675","DOI":"10.1097\/01.inf.0000172901.29621.e9"},{"key":"2021120902024342300_R12","unstructured":"Mendez R, Henderson F, Reisinger K, et al. Immunogenicity and safety of process upgrade varicella vaccine (PUVV) with new stabilizer as compared to PUVV with current stabilizer when administered concomitantly with M-M-RII in healthy children. Presented at the 22nd annual meeting of the European Society for Paediatric Infectious Diseases; May 26\u201328, 2004; Tampere, Finland"},{"key":"2021120902024342300_R13","doi-asserted-by":"crossref","unstructured":"Bell KN, Hogue CJ, Manning C, Kendal A. Risk factors for improper vaccine storage and handling in private provider offices. Pediatrics.\u20082001;107(6). Available at: www.pediatrics.org\/cgi\/content\/full\/107\/6\/e100","DOI":"10.1542\/peds.107.6.e100"},{"key":"2021120902024342300_R14","doi-asserted-by":"crossref","unstructured":"Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW. Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods.\u20081986;14:177\u2013188","DOI":"10.1016\/0166-0934(86)90048-0"},{"key":"2021120902024342300_R15","doi-asserted-by":"crossref","unstructured":"Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol.\u20081990;32:189\u2013193","DOI":"10.1002\/jmv.1890320310"},{"key":"2021120902024342300_R16","doi-asserted-by":"crossref","unstructured":"Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine.\u20081991;9:111\u2013116","DOI":"10.1016\/0264-410X(91)90266-9"},{"key":"2021120902024342300_R17","doi-asserted-by":"crossref","unstructured":"White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J.\u20081992;11:19\u201323","DOI":"10.1097\/00006454-199201000-00006"},{"key":"2021120902024342300_R18","doi-asserted-by":"crossref","unstructured":"Li S, Chan I, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J.\u20082002;21:337\u2013342","DOI":"10.1097\/00006454-200204000-00014"},{"key":"2021120902024342300_R19","doi-asserted-by":"crossref","unstructured":"Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med.\u20081985;4:213\u2013\u2013226","DOI":"10.1002\/sim.4780040211"},{"key":"2021120902024342300_R20","unstructured":"World Health Organization. Immunization Focus of Western Pacific Regional Office: Assessing New Vaccines for National Immunization Programmes\u2014A Framework to Assist Decision Makers. Geneva, Switzerland: World Health Organization; 2000"},{"key":"2021120902024342300_R21","unstructured":"Centers for Disease Control and Prevention. Notice to readers: guidelines for maintaining and managing the vaccine cold chain. MMWR Morb Mortal Wkly Rep.\u20082003;52:1023\u20131025"},{"key":"2021120902024342300_R22","unstructured":"World Health Organization. Global Programme for Vaccines and Immunization (GPV). The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec.\u20081998;10:64\u201371"},{"key":"2021120902024342300_R23","doi-asserted-by":"crossref","unstructured":"Heymann DL, Smith EL, Nakano JH, Jato JG, Martin GE, Maben GK. Further field testing of the more heat-stable measles vaccine in Cameroon. Br Med J (Clin Res Ed).\u20081982;285:531\u2013533","DOI":"10.1136\/bmj.285.6341.531"},{"key":"2021120902024342300_R24","unstructured":"Galazka A, Milstien J, Zaffran M. Thermostability of Vaccines: Global Programme for Vaccines and Immunization (GPV). Geneva, Switzerland: World Health Organization; 1998"},{"key":"2021120902024342300_R25","unstructured":"World Health Organization. Global Programme for Vaccines and Immunization (GPV): Safe Vaccine Handling, Cold Chain and Immunizations\u2014A Manual for the Newly Independent States. Geneva, Switzerland: World Health Organization; 1998"},{"key":"2021120902024342300_R26","unstructured":"World Health Organization, Department of Vaccines and Biologicals. Guidelines for Establishing or Improving Primary and Intermediate Vaccine Stores. Geneva, Switzerland: World Health Organization; 2002"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/119\/6\/e1299\/1119023\/zpe006070e1299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/119\/6\/e1299\/1119023\/zpe006070e1299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T08:57:16Z","timestamp":1639040236000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/119\/6\/e1299\/70636\/Comparison-of-the-Safety-and-Immunogenicity-of-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,1]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2007,6,1]]},"published-print":{"date-parts":[[2007,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-2283","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,1]]}}}